Gelonhui, December 20, 丨 Teyi Pharmaceutical announced that it recently signed a “Commissioning Agreement on the Pharmacological Mechanism and Substance Basis Research on the Pharmacological Mechanism and Substance Basis of Cough Relief Tablets for Treating Cough and Lung Inflammation after Influenza Virus Infection” with the aim of increasing its indications for airway inflammation, cough and phlegm increase caused by respiratory viral infections, and further enhancing product brand and marketing capabilities through research on the pharmacological mechanism and material basis of cough suppressants for treating cough and lung inflammation after influenza virus infection..